Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of QLM3003 ointment in adults with mild-to-moderate atopic dermatitis
CTR20250987Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2025
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of QLM3003 in atopic dermatitis (AD), sponsored by Qilu Pharmaceutical. Started May 2025; status: active.
02
Drugs
QLM3003
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20250987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250987.